Eloxx Pharma rises on progress update for cystic fibrosis therapy study

Eloxx Pharmaceuticals

07/07/2021 11:37

** Drug developer's shares  ELOX.O  up 3.6% at $2 premarket
    ** As of June end, ELOX has enrolled sufficient number of
patients to assess activity of its lead drug candidate, ELX-02,
to treat cystic fibrosis (CF), company says  urn:newsml:reuters.com:*:nGNX9hcQK0
    ** Company expects to present data from its ongoing
mid-stage study in Q4
    ** Data timing guidance narrowed to Q4 from H2, ELOX can
gain from successful Phase 2 study amid a series of
disappointing early to mid-stage CF clinical trials - B. Riley
Securities     
    ** Arrowhead Pharmaceuticals  ARWR.O  last week voluntarily
paused an early-stage trial of its experimental CF therapy
following an update from a chronic toxicology study in rats
 urn:newsml:reuters.com:*:nL3N2OE2NL
    ** CF is an inherited disorder involving a defective gene,
which can cause severe damage to the lungs, digestive system and
other organs in the body
    ** ELOX down 51.5% YTD, as of last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com))